Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10112655 | 0.96 | SLC6A3 (0.64) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL10112687 | 0.96 | SLC6A3 (0.64) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL25998749 | 0.86 | SLC6A3 (0.59) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL25998726 | 0.86 | SLC6A3 (0.59) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL14453323 | 0.85 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL637496 | 0.85 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5564447 | 0.85 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6886035 | 0.85 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL14453322 | 0.85 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL2142477 | 0.84 | SLC6A3 (0.56) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012135749-A2 | BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS | GENENTECH, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012088254-A1 | AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS | GENENTECH, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087336-A1 | AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS | GENENTECH, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2011130654-A1 | FOX03A AS PREDICTIVE BIOMARKER FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY | GENENTECH, INC. (US) | 2011-10-20 | — | — | WO | disclosed |